Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861068 | 0.87 | FDPS (0.42) | AHCYENPP1ENPP3 | |
| SCHEMBL3852157 | 0.86 | AHCY (0.46) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL3853185 | 0.86 | CDK1 (0.47) | AHCY | |
| SCHEMBL13714845 | 0.84 | FGFR1 (0.54) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL3852148 | 0.84 | FGFR1 (0.54) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL13714886 | 0.83 | AHCY (0.44) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL6004041 | 0.82 | AHCY (0.44) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL13714833 | 0.79 | ENPP1 (0.49) | AHCYENPP1ENPP3CYP3A4 | |
| SCHEMBL3861070 | 0.74 | FDPS (0.42) | AHCYENPP1ENPP3 | |
| SCHEMBL24860314 | 0.73 | ADORA2A (0.75) | AHCYADORA2AADORA2BADORA1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | AHCY 704/4885ADORA2A 214/4885ADORA2B 464/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | AHCY 704/4885ADORA2A 214/4885ADORA2B 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.